Relay Medical & Fio Commence COVID-19 Rapid Testing for U.S. Departing Passengers at Toronto Pearson Airport
Toronto, Ontario--(Newsfile Corp. - March 25, 2021) - Relay Medical Corp. (CSE: RELA) (OTCQB: RYMDF) (FSE: EIY2) ("Relay" or the "Company") and Fio Corporation ("Fio") - together Fionet Rapid Response Group ("FRR") announce that the Fionet Platform has been successfully deployed at Toronto Pearson International Airport ("Toronto Pearson") and currently managing COVID-19 rapid testing for passengers departing to the U.S.
- Toronto, Ontario--(Newsfile Corp. - March 25, 2021) - Relay Medical Corp. (CSE: RELA) (OTCQB: RYMDF) (FSE: EIY2) ("Relay" or the "Company") and Fio Corporation ("Fio") - together Fionet Rapid Response Group ("FRR") announce that the Fionet Platform has been successfully deployed at Toronto Pearson International Airport ("Toronto Pearson") and currently managing COVID-19 rapid testing for passengers departing to the U.S.
- Toronto Pearson is Canada's largest and busiest airport, serving more than 50 million passengers in 2019, and one of only four airports accepting international flights into Canada.
- Negative results from the Toronto Pearson testing program, including Antigen COVID-19 tests, can be relied on for travel to the U.S.
- Under the terms of the engagement with Toronto Pearson, the Fionet digital workflow, testing, and data infrastructure is deployed at Toronto Pearson to help manage COVID-19 testing for both passengers and employees.